Lentiviral vectors

Basic to translational

Toshie Sakuma, Michael A Barry, Yasuhiro H Ikeda

Research output: Contribution to journalArticle

150 Citations (Scopus)

Abstract

More than two decades have passed since genetically modified HIV was used for gene delivery. Through continuous improvements these early marker gene-carrying HIVs have evolved into safer and more effective lentiviral vectors. Lentiviral vectors offer several attractive properties as gene-delivery vehicles, including: (i) sustained gene delivery through stable vector integration into host genome; (ii) the capability of infecting both dividing and non-dividing cells; (iii) broad tissue tropisms, including important gene- and cell-therapy-target cell types; (iv) no expression of viral proteins after vector transduction; (v) the ability to deliver complex genetic elements, such as polycistronic or intron-containing sequences; (vi) potentially safer integration site profile; and (vii) a relatively easy system for vector manipulation and production. Accordingly, lentivector technologies nowhavewidespread use in basic biology and translational studies for stable transgene overexpression, persistent gene silencing, immunization, in vivo imaging, generating transgenic animals, induction of pluripotent cells, stem cell modification and lineage tracking, or site-directed gene editing. Moreover, in the present high-throughput '-omics' era, the commercial availability of premade lentiviral vectors, which are engineered to express or silence genome-wide genes, accelerates the rapid expansion of this vector technology. In the present review, we assess the advances in lentiviral vector technology, including basic lentivirology, vector designs for improved efficiency and biosafety, protocols for vector production and infection, targeted gene delivery, advanced lentiviral applications and issues associated with the vector system.

Original languageEnglish (US)
Pages (from-to)603-618
Number of pages16
JournalBiochemical Journal
Volume443
Issue number3
DOIs
StatePublished - May 1 2012

Fingerprint

Genes
Technology
HIV
Genome
Genetically Modified Animals
Tropism
Gene Silencing
Viral Proteins
Cell Lineage
Cell- and Tissue-Based Therapy
Transgenes
Genetic Therapy
Introns
Immunization
Stem Cells
Stem cells
Infection
Animals
Throughput
Availability

Keywords

  • Cell targeting
  • Central polypurine tract (cPPT)
  • Gene therapy
  • HIV-1
  • Lentivirus
  • Self-inactivating (SIN)

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Lentiviral vectors : Basic to translational. / Sakuma, Toshie; Barry, Michael A; Ikeda, Yasuhiro H.

In: Biochemical Journal, Vol. 443, No. 3, 01.05.2012, p. 603-618.

Research output: Contribution to journalArticle

Sakuma, Toshie ; Barry, Michael A ; Ikeda, Yasuhiro H. / Lentiviral vectors : Basic to translational. In: Biochemical Journal. 2012 ; Vol. 443, No. 3. pp. 603-618.
@article{50c8ec619c1341408c7e525e9f270732,
title = "Lentiviral vectors: Basic to translational",
abstract = "More than two decades have passed since genetically modified HIV was used for gene delivery. Through continuous improvements these early marker gene-carrying HIVs have evolved into safer and more effective lentiviral vectors. Lentiviral vectors offer several attractive properties as gene-delivery vehicles, including: (i) sustained gene delivery through stable vector integration into host genome; (ii) the capability of infecting both dividing and non-dividing cells; (iii) broad tissue tropisms, including important gene- and cell-therapy-target cell types; (iv) no expression of viral proteins after vector transduction; (v) the ability to deliver complex genetic elements, such as polycistronic or intron-containing sequences; (vi) potentially safer integration site profile; and (vii) a relatively easy system for vector manipulation and production. Accordingly, lentivector technologies nowhavewidespread use in basic biology and translational studies for stable transgene overexpression, persistent gene silencing, immunization, in vivo imaging, generating transgenic animals, induction of pluripotent cells, stem cell modification and lineage tracking, or site-directed gene editing. Moreover, in the present high-throughput '-omics' era, the commercial availability of premade lentiviral vectors, which are engineered to express or silence genome-wide genes, accelerates the rapid expansion of this vector technology. In the present review, we assess the advances in lentiviral vector technology, including basic lentivirology, vector designs for improved efficiency and biosafety, protocols for vector production and infection, targeted gene delivery, advanced lentiviral applications and issues associated with the vector system.",
keywords = "Cell targeting, Central polypurine tract (cPPT), Gene therapy, HIV-1, Lentivirus, Self-inactivating (SIN)",
author = "Toshie Sakuma and Barry, {Michael A} and Ikeda, {Yasuhiro H}",
year = "2012",
month = "5",
day = "1",
doi = "10.1042/BJ20120146",
language = "English (US)",
volume = "443",
pages = "603--618",
journal = "Biochemical Journal",
issn = "0264-6021",
publisher = "Portland Press Ltd.",
number = "3",

}

TY - JOUR

T1 - Lentiviral vectors

T2 - Basic to translational

AU - Sakuma, Toshie

AU - Barry, Michael A

AU - Ikeda, Yasuhiro H

PY - 2012/5/1

Y1 - 2012/5/1

N2 - More than two decades have passed since genetically modified HIV was used for gene delivery. Through continuous improvements these early marker gene-carrying HIVs have evolved into safer and more effective lentiviral vectors. Lentiviral vectors offer several attractive properties as gene-delivery vehicles, including: (i) sustained gene delivery through stable vector integration into host genome; (ii) the capability of infecting both dividing and non-dividing cells; (iii) broad tissue tropisms, including important gene- and cell-therapy-target cell types; (iv) no expression of viral proteins after vector transduction; (v) the ability to deliver complex genetic elements, such as polycistronic or intron-containing sequences; (vi) potentially safer integration site profile; and (vii) a relatively easy system for vector manipulation and production. Accordingly, lentivector technologies nowhavewidespread use in basic biology and translational studies for stable transgene overexpression, persistent gene silencing, immunization, in vivo imaging, generating transgenic animals, induction of pluripotent cells, stem cell modification and lineage tracking, or site-directed gene editing. Moreover, in the present high-throughput '-omics' era, the commercial availability of premade lentiviral vectors, which are engineered to express or silence genome-wide genes, accelerates the rapid expansion of this vector technology. In the present review, we assess the advances in lentiviral vector technology, including basic lentivirology, vector designs for improved efficiency and biosafety, protocols for vector production and infection, targeted gene delivery, advanced lentiviral applications and issues associated with the vector system.

AB - More than two decades have passed since genetically modified HIV was used for gene delivery. Through continuous improvements these early marker gene-carrying HIVs have evolved into safer and more effective lentiviral vectors. Lentiviral vectors offer several attractive properties as gene-delivery vehicles, including: (i) sustained gene delivery through stable vector integration into host genome; (ii) the capability of infecting both dividing and non-dividing cells; (iii) broad tissue tropisms, including important gene- and cell-therapy-target cell types; (iv) no expression of viral proteins after vector transduction; (v) the ability to deliver complex genetic elements, such as polycistronic or intron-containing sequences; (vi) potentially safer integration site profile; and (vii) a relatively easy system for vector manipulation and production. Accordingly, lentivector technologies nowhavewidespread use in basic biology and translational studies for stable transgene overexpression, persistent gene silencing, immunization, in vivo imaging, generating transgenic animals, induction of pluripotent cells, stem cell modification and lineage tracking, or site-directed gene editing. Moreover, in the present high-throughput '-omics' era, the commercial availability of premade lentiviral vectors, which are engineered to express or silence genome-wide genes, accelerates the rapid expansion of this vector technology. In the present review, we assess the advances in lentiviral vector technology, including basic lentivirology, vector designs for improved efficiency and biosafety, protocols for vector production and infection, targeted gene delivery, advanced lentiviral applications and issues associated with the vector system.

KW - Cell targeting

KW - Central polypurine tract (cPPT)

KW - Gene therapy

KW - HIV-1

KW - Lentivirus

KW - Self-inactivating (SIN)

UR - http://www.scopus.com/inward/record.url?scp=84860133437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860133437&partnerID=8YFLogxK

U2 - 10.1042/BJ20120146

DO - 10.1042/BJ20120146

M3 - Article

VL - 443

SP - 603

EP - 618

JO - Biochemical Journal

JF - Biochemical Journal

SN - 0264-6021

IS - 3

ER -